Literature DB >> 15047507

Interaction of the new ketolide ABT-773 (cethromycin) with human polymorphonuclear neutrophils and the phagocytic cell line PLB-985 in vitro.

Marie Thérèse Labro1, Houria Abdelghaffar, Catherine Babin-Chevaye.   

Abstract

A classical velocity centrifugation technique was used to study the in vitro uptake of the new ketolide ABT-773 by human polymorphonuclear neutrophils (PMNs) and a myelomonoblastic cell line, PLB-985, which can be differentiated into PMNs under certain culture conditions, compared to that of HMR 3004. ABT-773 was rapidly taken up by PMNs (cellular concentration to extracellular concentration ratio [C/E], about 34 at 30 s and up to 207 at 5 min), and uptake plateaued from 30 to 180 min (C/E, about 300). ABT-773 was accumulated significantly better than HMR 3004 from 5 to 180 min. Nondifferentiated PLB-985 cells (ND-PLB) accumulated significantly less ABT-773 and HMR 3004 than PMNs and PLB-985 cells differentiated into PMNs (D-PLB). Whatever the cell type and in contrast to the results obtained with HMR 3004, ABT-773 was mainly located in the cytosol (about 75%) and was rapidly released from loaded cells (about 40% at 5 min), followed by a plateau, likely owing to avid reuptake. Verapamil and H89, an inhibitor of protein kinase A, increased drug efflux. Uptake was sensitive to external pH, and the activation energy was moderate (about 50 kJ/mol). The existence of an active transport system on the PMN membrane was suggested by the following findings: concentration-dependent and saturable uptake (V(max), about 10,000 ng/2.5 x 10(6) PMNs/5 min; K(m), about 60 microg/ml) the inhibitory effects of PMN activators or inhibitors (phorbol myristate acetate, verapamil, Ni(2+)) and the significantly decreased levels of accumulation by killed cells and cells treated at low temperatures. In addition, various macrolides impaired ABT-773 uptake, contrary to the findings for the quinolone levofloxacin. ND- and D-PLB also presented saturation kinetics that defined an active transport system (V(max) and K(m) values were similar to those obtained with PMNs), but the activation pathway of the carrier system did not seem to be fully functional in ND-PLB. As has been observed with other erythromycin A derivatives, ABT-773 impaired oxidant production by phagocytes in a time- and concentration-dependent manner. These data extend our previous results on the existence of an active transport system common to all macrolides and ketolides, at least in PMNs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047507      PMCID: PMC375272          DOI: 10.1128/AAC.48.4.1096-1104.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Cellular uptake of two fluoroketolides, HMR 3562 and HMR 3787, by human polymorphonuclear neutrophils in vitro.

Authors:  H Abdelghaffar; D Vazifeh; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

2.  The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.

Authors:  F J Boswell; J M Andrews; J P Ashby; C Fogarty; N P Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

3.  Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils.

Authors:  D Vazifeh; A Preira; A Bryskier; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

4.  Mechanism of azithromycin uptake in human polymorphonuclear leucocytes.

Authors:  H Laufen; A Wildfeuer; P Lach
Journal:  Arzneimittelforschung       Date:  1990-06

5.  The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells.

Authors:  C Miossec-Bartoli; L Pilatre; P Peyron; E N N'Diaye; V Collart-Dutilleul; I Maridonneau-Parini; A Diu-Hercend
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages.

Authors:  M B Carlier; B Scorneaux; A Zenebergh; J F Desnottes; P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

7.  Ketolides lack inducibility properties of MLS(B) resistance phenotype.

Authors:  A Bonnefoy; A M Girard; C Agouridas; J F Chantot
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

8.  Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci.

Authors:  Virginia D Shortridge; Ping Zhong; Zhensheng Cao; Jill M Beyer; Laurel S Almer; Nancy C Ramer; Stella Z Doktor; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.

Authors:  M W Pletz; V Preechachatchaval; J Bulitta; M Allewelt; O Burkhardt; H Lode
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

10.  Investigation of dirithromycin and erythromycylamine uptake by human neutrophils in vitro.

Authors:  E M Mtairag; H Abdelghaffar; M T Labro
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

View more
  3 in total

1.  Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin.

Authors:  Martina Bosnar; Zeljko Kelnerić; Vesna Munić; Vesna Eraković; Michael J Parnham
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 2.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

3.  Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals.

Authors:  Monica Venner; Jette Peters; Nina Höhensteiger; Birthe Schock; Alexa Bornhorst; Markus Grube; Ulrike Adam; Eberhard Scheuch; Werner Weitschies; Dieter Rosskopf; Heyo K Kroemer; Werner Siegmund
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-15       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.